SEC Form 4 · accession 0001209191-19-014296

SANGAMO THERAPEUTICS, INC · SGMO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Feb 25, 2019

Accepted (ET)

Feb 27, 2019 · 8:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001001233

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 25, 2019	A	63,250	$0.00	A	90,776	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right-to-Buy)^F2	$9.03	Feb 25, 2019	A	379,500	A	—	Feb 24, 2029	Common Stock	379,500	379,500	D

F1Represents 63,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 21,000 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.
F2One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.